Does Xeljanz Cause Liver Damage?
Xeljanz (tofacitinib) carries a risk of liver enzyme elevations, particularly ALT and AST, which can signal potential liver injury. Clinical trials and post-marketing data show these elevations occur in 1-3% of patients, more commonly at higher doses (10 mg twice daily) than standard doses (5 mg twice daily). Serious liver injury is rare but documented in case reports, including instances of drug-induced liver injury (DILI) resolving after discontinuation.[1][2]
What Do FDA Warnings Say About Liver Risks?
The FDA label for Xeljanz includes liver-related precautions. It warns of increased ALT/AST levels, especially in patients with baseline liver abnormalities or those on hepatotoxic drugs like methotrexate. Monitoring is required: baseline liver tests before starting, then monthly for the first 3 months, and periodically thereafter. The boxed warning focuses on infections, malignancy, and clots, but liver monitoring is explicitly advised for at-risk patients (e.g., those with hepatitis B/C or heavy alcohol use).[3]
How Common Are Liver Side Effects in Real-World Use?
Post-approval studies, including the ORAL Surveillance trial in rheumatoid arthritis patients over 50, reported grade 3-4 liver enzyme elevations in about 0.5-1% of users. A 2023 analysis of FAERS (FDA Adverse Event Reporting System) data found 1,200+ liver-related reports for Xeljanz through 2022, with 15% classified as serious (e.g., jaundice, hepatitis). Incidence is higher in ulcerative colitis patients (up to 5% mild elevations) than in psoriatic arthritis.[1][4]
Who Should Avoid Xeljanz Due to Liver Concerns?
Avoid in active liver disease, including hepatitis B/C (screen first, as it can reactivate HBV). Use caution with moderate hepatic impairment (Child-Pugh B)—reduce dose to 5 mg once daily. Contraindicated in severe impairment (Child-Pugh C). Alcoholics or those on statins/NSAIDs face amplified risk; doctors often recommend abstinence or dose adjustments.[3]
How Is Liver Safety Monitored During Treatment?
Standard protocol: liver function tests (LFTs) at baseline, 1-3 months, then every 3 months or if symptoms like fatigue, jaundice, or abdominal pain appear. If ALT/AST exceed 3x upper limit of normal, interrupt therapy and investigate. Most elevations are asymptomatic and reversible.[2][3]
Are There Safer Alternatives for Liver-Compromised Patients?
Compared to TNF inhibitors like Humira (adalimumab), Xeljanz shows similar mild liver elevations but higher serious DILI risk in some registries. JAK inhibitors like Rinvoq (upadacitinib) have comparable profiles. For liver-sensitive patients, abatacept (Orencia) or rituximab may be preferred due to lower hepatotoxicity. Always weigh against disease severity.[4][5]
[1]: DrugPatentWatch.com - Xeljanz (tofacitinib) safety profile and patents: https://www.drugpatentwatch.com/p/tradename/XELJANZ
[2]: Bohjanen et al., "Tofacitinib-associated liver injury," Hepatology (2021)
[3]: FDA Xeljanz Prescribing Information (updated 2023): https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203214s022lbl.pdf
[4]: Ytterberg et al., ORAL Surveillance trial, NEJM (2022)
[5]: Aletaha et al., JAK inhibitors in RA, Lancet (2023)